Literature DB >> 30333323

Coordination of ENT2-dependent adenosine transport and signaling dampens mucosal inflammation.

Carol M Aherne1,2, Colm B Collins2,3, Caroline R Rapp1,2, Kristine E Olli1,2, Loni Perrenoud1,2, Paul Jedlicka4, Jessica L Bowser5, Tingting W Mills6, Harry Karmouty-Quintana6, Michael R Blackburn6, Holger K Eltzschig1,5.   

Abstract

Intestinal epithelial barrier repair is vital for remission in inflammatory bowel disease (IBD). Extracellular adenosine signaling has been implicated in promoting restoration of epithelial barrier function. Currently, no clinically approved agents target this pathway. Adenosine signaling is terminated by uptake from the extracellular space via equilibrative nucleoside transporters (ENTs). We hypothesized that ENT inhibition could dampen intestinal inflammation. Initial studies demonstrated transcriptional repression of ENT1 and ENT2 in IBD biopsies or in murine IBD models. Subsequent studies in mice with global Ent1 or Ent2 deletion revealed selective protection of Ent2-/- mice. Elevated intestinal adenosine levels in conjunction with abolished protection following pharmacologic blockade of A2B adenosine receptors implicate adenosine signaling as the mechanism of gut protection in Ent2-/- mice. Additional studies in mice with tissue-specific deletion of Ent2 uncovered epithelial Ent2 as the target. Moreover, intestinal protection provided by a selective Ent2 inhibitor was abolished in mice with epithelium-specific deletion of Ent2 or the A2B adenosine receptor. Taken together, these findings indicate that increased mucosal A2B signaling following repression or deletion of epithelial Ent2 coordinates the resolution of intestinal inflammation. This study suggests the presence of a targetable purinergic network within the intestinal epithelium designed to limit tissue inflammation.

Entities:  

Keywords:  Gastroenterology; Inflammatory bowel disease

Mesh:

Substances:

Year:  2018        PMID: 30333323      PMCID: PMC6237472          DOI: 10.1172/jci.insight.121521

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  78 in total

1.  Regional distribution of solute carrier mRNA expression along the human intestinal tract.

Authors:  Yvonne Meier; Jyrki J Eloranta; Jutta Darimont; Manfred G Ismair; Christian Hiller; Michael Fried; Gerd A Kullak-Ublick; Stephan R Vavricka
Journal:  Drug Metab Dispos       Date:  2007-01-12       Impact factor: 3.922

2.  ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors.

Authors:  Yu Chen; Ross Corriden; Yoshiaki Inoue; Linda Yip; Naoyuki Hashiguchi; Annelies Zinkernagel; Victor Nizet; Paul A Insel; Wolfgang G Junger
Journal:  Science       Date:  2006-12-15       Impact factor: 47.728

Review 3.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

4.  Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test.

Authors:  Vanya A Gerova; Simeon G Stoynov; Dimitar S Katsarov; Dobrin A Svinarov
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

Review 5.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

6.  Differential inhibition of nucleoside transport systems in mammalian cells by a new series of compounds related to lidoflazine and mioflazine.

Authors:  D A Griffith; A R Conant; S M Jarvis
Journal:  Biochem Pharmacol       Date:  1990-11-15       Impact factor: 5.858

Review 7.  Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases.

Authors:  William J Sandborn; Stephen Hanauer; Gert Van Assche; Julián Panés; Stephanie Wilson; Joel Petersson; Remo Panaccione
Journal:  J Crohns Colitis       Date:  2014-04-06       Impact factor: 9.071

8.  A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis.

Authors:  George Gallos; Thomas D Ruyle; Charles W Emala; H Thomas Lee
Journal:  Am J Physiol Renal Physiol       Date:  2005-03-22

9.  HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia.

Authors:  Holger K Eltzschig; Parween Abdulla; Edgar Hoffman; Kathryn E Hamilton; Dionne Daniels; Caroline Schönfeld; Michaela Löffler; German Reyes; Michael Duszenko; Jorn Karhausen; Andreas Robinson; Karen A Westerman; Imogen R Coe; Sean P Colgan
Journal:  J Exp Med       Date:  2005-12-05       Impact factor: 14.307

10.  Adenosine Receptor Stimulation by Polydeoxyribonucleotide Improves Tissue Repair and Symptomology in Experimental Colitis.

Authors:  Giovanni Pallio; Alessandra Bitto; Gabriele Pizzino; Federica Galfo; Natasha Irrera; Francesco Squadrito; Giovanni Squadrito; Socrate Pallio; Giuseppe P Anastasi; Giuseppina Cutroneo; Antonio Macrì; Domenica Altavilla
Journal:  Front Pharmacol       Date:  2016-08-23       Impact factor: 5.810

View more
  19 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy.

Authors:  Ezgi Elmas; Noushin Saljoughian; Marcelo de Souza Fernandes Pereira; Brian P Tullius; Kinnari Sorathia; Robin J Nakkula; Dean A Lee; Meisam Naeimi Kararoudi
Journal:  Front Oncol       Date:  2022-04-05       Impact factor: 5.738

Review 3.  Disease Mechanisms of Perioperative Organ Injury.

Authors:  Catharina Conrad; Holger K Eltzschig
Journal:  Anesth Analg       Date:  2020-12       Impact factor: 6.627

4.  Special issue on hypoxia.

Authors:  Eui-Ju Yeo
Journal:  Exp Mol Med       Date:  2019-06-20       Impact factor: 8.718

Review 5.  Dysregulation of Adenosinergic Signaling in Systemic and Organ-Specific Autoimmunity.

Authors:  Marta Vuerich; Rasika P Harshe; Simon C Robson; Maria Serena Longhi
Journal:  Int J Mol Sci       Date:  2019-01-27       Impact factor: 5.923

Review 6.  Hypoxia signaling in human diseases and therapeutic targets.

Authors:  Jae W Lee; Junsuk Ko; Cynthia Ju; Holger K Eltzschig
Journal:  Exp Mol Med       Date:  2019-06-20       Impact factor: 8.718

Review 7.  CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers.

Authors:  Jerry B Harvey; Luan H Phan; Oscar E Villarreal; Jessica L Bowser
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

8.  Resolution metabolomes activated by hypoxic environment.

Authors:  Paul C Norris; Stephania Libreros; Charles N Serhan
Journal:  Sci Adv       Date:  2019-10-23       Impact factor: 14.136

9.  Decreased Frequency of Intestinal CD39+ γδ+ T Cells With Tissue-Resident Memory Phenotype in Inflammatory Bowel Disease.

Authors:  Jana Libera; Melanie Wittner; Marcus Kantowski; Robin Woost; Johanna M Eberhard; Jocelyn de Heer; Dominik Reher; Samuel Huber; Friedrich Haag; Julian Schulze Zur Wiesch
Journal:  Front Immunol       Date:  2020-09-24       Impact factor: 7.561

10.  Inflammatory Bowel Diseases: It's Time for the Adenosine System.

Authors:  Luca Antonioli; Matteo Fornai; Carolina Pellegrini; Lorenzo Bertani; Zoltan H Nemeth; Corrado Blandizzi
Journal:  Front Immunol       Date:  2020-07-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.